| 吉西他滨联合诺维本治疗晚期乳腺癌的临床观察 |
| |
| 引用本文： | 赵忠全,欧阳学农,陈碧菌.吉西他滨联合诺维本治疗晚期乳腺癌的临床观察[J].福州总医院学报,2010(4). |
| |
| 作者姓名： | 赵忠全 欧阳学农 陈碧菌 |
| |
| 作者单位： | 福州总医院肿瘤科; |
| |
| 摘 要： | 目的:观察吉西他滨(健择)联合诺维本方案(GN方案)治疗蒽环类或紫杉类耐药性晚期乳腺癌的疗效与安全性。方法:39例对蒽环类或紫杉类耐药性晚期乳腺癌患者,接受GEM1000mg/m2静滴,第1、8天,NVB25mg/m2,静滴,第1、8天,每21天为1周期,至少应用2周期。以WHO标准评价疗效和毒性。结果:39例患者中,CR2例(5.1%),PR18例(46.2%),SD11例(28.2%),PD8例(20.5%),RR为51.3%。中位缓解期7.9个月(4～23个月)。主要不良反应为骨髓抑制、消化道反应,均为可逆性。结论:GP方案治疗蒽环类或紫杉类耐药性晚期乳腺癌疗效较好,毒性反应可以耐受,是二线治疗蒽环类或紫杉类耐药性晚期乳腺癌的有效解救方案。
|
| 关 键 词： | 乳腺癌 吉西他滨 诺维本 化疗 |
Gemcitabine plus Vinorelbine as a second-line chemotherapy regimen for patients wiUl advanced breast cancer |
| |
| Abstract: | Objective:To investigate efficacy and safety of gemcitabine and Vinorelbine as a second line chemotherapy regimen in the patients with advanced breast cancer previously resistant to anthracycline or taxanes.Method:29 patients with advanced breast cancer resistant to anthracycline or taxane were treated consisted of gemcitabine 1200mg/m2 i.v,on day 1 and day8;Vinorelbine 250mg/m2 i.v,on day 1 and day 8;21days a cycle for 2 cycles at least.Results:Amomg the 39 cases 5 cases(2.1%)were completely relieved(CR),1... |
| |
| Keywords: | Gemcitabine Vinorelbine Chemotherapy Breast canner |
| 本文献已被 CNKI 等数据库收录！ |
|
